BRCA1 and neoplasm: Possible reasons may be temporal and spatial heterogeneity in which differences in BRCA1 deactivation (LOH or promoter hypermethylation in combination with mutation) throughout the tumor take place during therapy selection over time, or a relatively low sensitivity of techniques in earlier reports compared to our assay.